Highlights
- Chrysos Corporation (ASX:C79) reported unaudited July-October FY27 Revenue of AUD 36.7 million.
- PhotonAssay sample volumes increased 43% to 4.91 million over the four months.
- Fifteen new unit leases brought the total contracted fleet to 97 units.
- FY27 guidance remains AUD 108-118 million in revenue and AUD 35-42 million in EBITDA.
Chrysos Corporation Limited develops and leases PhotonAssay technology for rapid analysis of mineral samples at Mining and laboratory sites. On November 19, 2026, Chrysos Corporation (ASX:C79) traded at AUD 6.79, up 10.77% during the session. Its same-day pre-AGM update reported increased sample volumes, newly contracted units and reaffirmed FY27 guidance.
Four-Month Trading Update and Sample Volumes
Chrysos' November 19 pre-AGM trading update covered July through October 2026. The company reported unaudited revenue of AUD 36.7 million, 27% above the prior corresponding period. PhotonAssay samples processed increased 43% to 4.91 million, with a monthly record of 1.36 million in October. Sample growth is useful because a deployed machine can generate recurring minimum payments and additional fees linked to use. The four-month figures are not audited full-year results, and the difference between sample growth and revenue growth reflects the structure and mix of payments.
Unit Deployment and Contract Pipeline
The trading update stated that six units had been deployed during FY27 and a further six were in the deployment process, taking the installed fleet to 51 after a unit was decommissioned. Fifteen new Lease contracts had been signed in FY27, bringing the contracted fleet to 97 units. A signed contract does not mean the equipment has already been installed or is producing assay revenue. The lag between contracting, manufacture, shipping, commissioning and customer use remains a central Factor when evaluating the relationship between a lease pipeline and reported income. The company also indicated fleet availability above 90%.
Revenue Composition and FY27 Guidance
For the July-October period, Chrysos reported AUD 22.6 million of minimum monthly assay payments and AUD 13.7 million of additional assay charges, alongside other revenue. Additional assay charges increased more rapidly than fixed minimum payments, reflecting higher utilisation of deployed equipment. Management reaffirmed FY27 revenue guidance of AUD 108 million to AUD 118 million and EBITDA guidance of AUD 35 million to AUD 42 million. These ranges are expectations, not achieved financial results, and the company expressed them on a constant-currency basis. Contract commissioning and end-market activity influence the ultimate FY27 outcome.
Capital Position and Execution Requirements
Chrysos reported AUD 19.5 million of cash at October 31, 2026, and AUD 120 million of undrawn Debt capacity under its syndicated facility. Cash and an undrawn Facility are different forms of Liquidity and should not be combined without distinguishing availability from funds already held. Expanding a deployed equipment fleet requires Manufacturing capacity, installation, technical support and maintenance. Capital expenditure, customer deployment timing and servicing costs will affect free Cash Flow even where Demand indicators improve. Growth in sample volumes should therefore be read alongside cash generation, utilisation and unit economics.
Monitoring the Next Set of Results
The next milestones are further unit installations, conversion of the 97 contracted units into productive deployments, monthly sample throughput and the mix of fixed versus usage-related charges. Geographic expansion also requires customer laboratories and mine sites to be operationally ready for equipment. Chrysos previously reported FY26 revenue of AUD 88.1 million and EBITDA of AUD 27.2 million, providing a completed annual reporting base for the new guidance. Management's anticipated deployment trajectory remains forward-looking until individual units are installed. The trading update's release date does not by itself establish a causal explanation for the November 19 share price movement.
Key Insights
Chrysos reported higher sample volumes and an expanded contracted fleet in its November pre-AGM update while reaffirming FY27 guidance. Deployment schedules, usage charges and liquidity remain central reporting measures. Higher utilisation of installed units can increase usage-related charges without requiring an equal increase in installed machines. Nevertheless, future revenue still depends on customers maintaining volumes and making payments under their agreements.






Please wait processing your request...